Remove category
article thumbnail

How to Mitigate Ethical Challenges of AI-Driven Healthcare

Healthcare IT Today

Data analytics can be broken down into four distinct categories — diagnostic, descriptive, prescriptive and predictive — all of which analyze both current and historical data to predict certain outcomes as they relate to an individual. Another major ethical concern of AI use surrounds the principle of informed consent.

article thumbnail

OIG Advisory Opinion Alert: Yet Another Favorable Decision for Medical Device Manufacturers

Healthcare Law Blog

The three-component Therapy includes the following: (1) a device to process patient bone marrow (after an extraction procedure); (2) a device to re-inject processed bone marrow into cardiac tissue; and (3) an FDA-approved guide catheter to facilitate placement of processed bone marrow into cardiac issue.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Personalized Medicine: Consumer Concerns About Coverage, Affordability and Privacy

Health Populi

This is important because in 2017, one in four new drugs approved by the FDA were designed to treat a small population, falling. into the precision medicine category. Autonomy refers to data subjects’ (patients’) informed consent as a precondition of collecting personal health information agreeing to further uses.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2023 – January

SQA

Of interest is a reference to the FDA’s draft document “Computer Software Assurance for Production and Quality System Software,” which was recently published on 13 September 2022. PCPC looks forward to working with the FDA and key stakeholders to implement this important legislation.

article thumbnail

Who Needs a Lawyer in the Eleventh Circuit?

Drug & Device Law

The plaintiff in Jacob sued the manufacturer of a Class III, FDA premarket-approved medical device. First, the plaintiff’s non-parallel claims were “preempted to the extent” that they would have imposed “alleged labeling or manufacturing requirements that are different from, or in addition to, those imposed by the FDA.” 341 (2001).